


MISSION STATEMENT

At Renovatech Industries, our mission is to revolutionize healthcare through the delivery of comprehensive, multi-specialty medical services. We specialize in the latest technologies and clinical protocols through the continuous efforts of our dedicated research and development team, ensuring cutting-edge advancements. Our commitment is to improve patient outcomes by integrating innovative solutions and empowering communities with compassionate, evidence-based care, while fostering global partnerships to drive healthcare excellence internationally.



Amniotic Membrane Wound Covering & Barrier

Biologic protection. Simplicity in healing.



WHAT IS RENOVAGRAFT?

RenovaGraft™ is a minimally manipulated, dehydrated amniotic membrane product developed for homologous use as a wound covering and protective barrier. Sourced from full-term placental tissue, RenovaGraft retains the structural integrity and bioactive matrix of native amnion to support wound protection and closure in both acute and chronic settings.

- Natural barrier to certain contaminants
- Conforms to complex anatomies
- Applicable in complex wound clinics/inpatient settings
- Meets FDA 21 CFR 1271 HCT/P 361 regulatory criteria

CLINICAL USE

- Diabetic ulcers
- Pressure ulcers
- Venous stasis ulcers
- Wounds with exposed tendon, bone, or fascia

COMPOSITION


- Collagen Types I, III, IV, and V
- Laminin
- Fibronectin
- Hyaluronic Acid

BENEFITS OF RENOVAGRAFT

-  **Single-layer Amniotic Matrix**
Providing a resilient extracellular structure while preserving native ECM
-  **No-Side-Specific Orientation**
Apply in any direction – reduces surgical placement errors
-  **Immune-Privileged**
Low immunogenicity for reduced risk of adverse reaction
-  **High Conformability & Tensile Strength**
Effortlessly contours to wounds, even with exposed anatomy
-  **Flexible Hydration**
Can be applied hydrated or dehydrated to match clinician preference
-  **Ambient Storage**
No refrigeration required

Before & After Utilizing RenovaGraft

36 Days Diabetic Foot Ulcer Healed



6 Weeks Diabetic Foot Ulcer Healed




The patient had previously been treated with traditional wound care including medicinal honey, oral antibiotics, offloading, and weekly debridement. These methods did not work. Our amniotic allograft product provided full wound closure in 6 weeks

30 Days Venous Leg Ulcer Healed

A 74 YEAR OLD MALE with a history of diabetes, GERD, COPD, hypertension, atrial fibrillation, and hypercholesterolemia presented for an urgent visit due to left lower extremity ulcerations. The patient has a history of venous insufficiency and venous ulcerations.

Location: Left leg
Wound type: Venous ulcer
Weeks to resolution: 4
Total number of RenovaGraft applications: 3



Sizes: (A) 6 x 4.5 x 0.1 cm | (B) 2.5 x 3 x 0.1 cm

Sizes: (A) 6 x 4.5 x 0.1 cm | (B) 2.5 x 3 x 0.1 cm

Amniotic tissue is a regenerative biofactory, with key components known to optimize the wound healing environment.



Includes cytokines, amino acids, carbohydrates, hyaluronic acid, and cellular components.



Contains key growth factors and extracellular matrix proteins.



Offers anti-inflammatory, anti-bacterial, re-epithelialization, and anti-fibrotic properties.



Has published studies on its benefits and efficacy in woundcare dating back over 100 years.



Mitigates the expression of class II antigens, minimizing immunogenicity and reducing the risk of adverse reaction.

A leg is amputated due to diabetes every 30 seconds worldwide, RenovaGraft can prevent that.

Global Impact of Diabetes

Per International Diabetes Foundation - over 537 million people worldwide have diabetes today

- Global Prevalence of Diabetes - 9.8% of Population Ages 20-79 Years Old
- Country Impacts Range from <5% up to 30% of Populations
- 6.7 Million deaths per year >12 deaths every minute
- For People <60 Years of Age, % of Deaths Attributable to Diabetes - 32.6%
- Forecast to >783M People Impacted by 2045

Global TOTAL Health Expenditure - \$966B USD in 2021

The Growing Impact of Foot Ulcers

- Over 100 million people worldwide suffer from foot ulcers (IDF data)
- Global Foot Ulcer Treatment Market projected to grow from \$6B (2021) to \$12B (2028)
- Neuropathy Treatment Market estimated between \$5.4B (360i Research) and >\$9B (Data Bridge)

Our Commitment to the Community:

- Patient Care & Safety as top priorities
- Partnering with leading vascular treatment centers for early adoption
- Ongoing product and technology innovation to ensure excellence in care

POTENTIAL BENEFITS OF AMNIOTIC MEMBRANE GROWTH FACTORS:^{3*}

- Non-Immunogenic
- Anti-bacterial
- Anti-inflammatory
- Tissue regeneration/remodeling
- Anti-adhesive/anti-scarring
- Anti-microbial

The placenta contains growth factors and proteins that stimulate the body's own healing mechanism, reducing pain, inflammation, and scar tissue.⁴

- Platelet Derived Growth Factor (PDGF) A & B
- Vascular Endothelial Growth Factor (VEGF)
- Transforming Growth Factor beta (TGFβ)
- Fibroblast Growth Factor (FGF)
- Epidermal Growth Factor (EGF)
- Tissue Inhibitors of Metalloproteinases (TIMPs)
- Collagen Types I, III, IV, V, VII
- Laminin
- Fibronectin
- Proteoglycans
- Hyaluronic Acid (HA)

Ordering Information

Product Description	Size	Product Code
RenovaGraft®	2 × 2 cm	AMN-22
	2 × 4 cm	AMN-24
	4 × 4 cm	AMN-44
	4 × 8 cm	AMN-48

1. Sinno, Prakash. Plast Surg Int. 2013;146764

2. Spoerl, et al. Ophthalmic Res. 2004;36(2):71-7

3. Martin, et al. Encyclopedia Of Reproduction, 2018;3:387-398

4. Mamede, et al. Cell Tissue Res. 2012;349:447-458

*Based on published studies; not specific to RenovaGraft Amniotic Membranes

Tissue Recovery & Processing

Amniotic Membranes are donated by healthy, pre-screened, consenting women in the US, and processed in accordance with

TISSUE COLLECTION

Placental tissue is donated from live births in the U.S. without harming the mother or baby

DONOR SCREENING

A thorough medical and social history is obtained for each donor to ensure eligibility requirements are met

INFECTIOUS DISEASE TESTING


- HBsAg
- HBcAb
- HCV NAT
- HIV NAT
- HIV 1/2Ab
- WNV NAT
- HTLV/II Ab
- RPR/STS

TISSUE PROCESSING

All tissue undergoes a proprietary cleansing process to remove blood contaminants and reduce bioburden

TISSUE STERILIZATION

Tissue is sterilized for an additional level of safety, achieving a sterility assurance level (SAL) of 10.⁶



**RENOVATECH
INDUSTRIES**

RENOVATECH INDUSTRIES